GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout
Potential Best-In-Class Drug
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.
GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.